EUROPEAN COMMISSION
JOINT RESEARCH CENTRE

Directorate F – Health and Food
Disease Prevention

Annual Declaration of Interests[1] (DoI) form
(v2, 01 July 2026)

European Commission initiative on Lung Cancer (EC-LuC)

Please answer each of the questions below.
If the answer to any of the questions is "Yes"[2], please complete the corresponding fields, describing the circumstances, as appropriate.

If you do not submit a filled-in and signed DoI form, please consider that you cannot be involved in the EC-LuC activities.
If you do not disclose relevant activities of interest for the EC-LuC, your role may be revised.

[1] According to EC's Decision C(2016) 3301 establishing horizontal rules on the creation and operation of Commission expert groups, Articles 2(4) and 10, each member of an expert group has to complete a DoI form
https://ec.europa.eu/transparency/documents-register/detail?ref=C(2016)3301&lang=en

[2] Answering "Yes" to the questions on this form does not automatically limit your participation in the EC-LuC activities. Your answers will be reviewed to determine whether you have a conflict of interest (CoI) (*i.e.* any interest that may affect, or may reasonably be perceived to affect, an expert's objectivity and independence).

Name and Surname:	**Anne-Marie Baird**

Activities (2021 - 2025)	**Yes/No**	**Period (From - To)**	**Information**	**Details**
1. Do you have current investments[3] in a legal entity[4] with an interest related to lung cancer which either: **• has a value of more than 10.000 EUR, or** **• entitles you to a voting right of 5% or more?**	Yes ☐ No ☒	01/2021 – 12/2025	NA	NA

[3] **Investments** refer to stocks, bonds, stock options, other securities as well as to commercial business interests (*e.g.*, proprietorships, partnerships, joint ventures, board memberships, controlling interest in a company).

[4] **Legal entity** refers to any commercial business, industry association, consultancy, research institution or other enterprise whose funding is significantly derived from commercial sources. It also includes independent own commercial businesses, law offices, consultancies or similar.

Activities (2021 - 2025)	Yes/No	Period (From - To)	Information	Details
2. Within the past 5 years, were you employed (remunerated or non-remunerated post) or have you had any other professional relationship with a legal entity or any other body, with an interest related to lung cancer? **A. Employment**	Yes ☒ No ☐	01/2021 – Ongoing	• Trinity College Dublin • Dublin, Ireland • Public (University) • Academic salary	Senior Research Fellow: Academic research and teaching in translational cancer biology, including supervision, grant writing, and laboratory research.

Activities (2021 - 2025)	Yes/No	Period (From - To)	Information	Details
B. Consultancy, including advisory activities	Yes ☒ No ☐	01/2021 – 12/2025	2025: art tempi communications gmbh/Online/Private entity/350 euro 2025: AstraZeneca/In person/Private entity/363.21 euro 2024: Medscape Education/Online/Private entity/2300 euro 2024: Janssen (J&J)/In person/Private entity/980 euro 2023: Medscape Education/Online/Private entity/2531 euro 2023: AstraZeneca/In person/Private entity/500 euro 2022: Roche/In person/Private entity/495 euro 2022: EU commission/Online/Public/450 euro 2022: MI&T srl/Online/Private entity/700 euro 2021: Darmah Market Research/Phone/Private entity/150 euro	2025: Patient Advocate Lung Cancer for European Awareness Campaign 2025: Panel speaker at the AZ Global Lung Medical & Diagnostics Summit. Total includes speaker fee/taxi reimbursement. (Flight and accommodation were covered directly by AZ). 2024: Webinar speaker on 'Managing Extensive-Stage SCLC in the Real-World: Sharing Clinician and Patient Perspectives.' 2024: Speaker at their LCNUK Symposium (Flight/Accommodation & Registration costs were covered directly by company) 2023: Webinar speaker on 'Early-Stage Resectable Non-Small Cell Lung Cancer: Sharing Patient Perspectives' 2023: Talk about lung cancer as part of their lung cancer awareness month activities (Talk in 2022; payment received in 2023) 2022: Talk about lung cancer as part of their lung cancer awareness month activities 2022: Took part in first call in reviewing applications for Topic 3 (HORIZON-JU-IHI-2022-01-single-stage) 2022: Talk as part of the 'Second International Summit on Lung Cancer' 2021: Phone call to discuss lung cancer challenges

Activities (2021 - 2025)	Yes/No	Period (From - To)	Information	Details
C. Non-remunerated post	Yes ☒ No ☐	01/2021 – 12/2025	2025-Present: Member of IASLC Women in Thoracic Oncology Taskforce/Online and in person/Private entity/no renumeration 2023-Present: Member of IASLC DEI Taskforce/Online and in person/Private entity/no renumeration Approx. 2023-Present: Member ETOP Scientific committee/Online and in person/Private entity/No remuneration bar reimbursement for expenses incurred (i.e., flights to attend meetings) Approx. 2021-Present: IASLC STARS Mentor/Online and in person/Private entity/Webinar token (2022 – 443 euro; 2023 – 449.86 euro) Approx. 2021-Present: Member/Treasurer/Now Vice chairperson of the Irish Lung Cancer Community (ILCC)/Private entity/Online and in person/No renumeration bar reimbursement for expenses incurred. Approx. 2021/2022-Present: Member of Steering committee for a Roche clinical trial/Online/Private entity/No renumeration Apr. 2020-Apr. 2025: President of Lung Cancer Europe (LuCE)/Online and in person/Non profit/No remuneration received bar reimbursement for expenses incurred (i.e., flights to attend meetings).	IASLC: Contributing to IASLC activities on this topic. IASLC: Contributing to IASLC activities on this topic. ETOP: Contributing to multidisciplinary discussions on thoracic oncology research priorities. STARS mentor: The role is unpaid however, I received a token of appreciation for webinars given as well as flight/hotel/registration costs covered for World Conference on Lung Cancer (2023-2025). ILCC: Co-founder, Past Treasurer, Current Vice chairperson - supporting governance, finances, and national advocacy activities. Roche: Contributing patient perspectives on study LuCE: Provided strategic leadership and consensus-building on advocacy and policy priorities. As part of this I served as the European Cancer Organisations Patient Advisory Committee representative for LuCE (2018-2025) and serve as their representative on the ESMO Patient Advocacy Working Group (2025-Present).

Activities (2021 - 2025)	Yes/No	Period (From - To)	Information	Details
D. Legal representation[5]	Yes ☒ No ☐	04/2024 – present	Irish Lung Cancer Community/Online and in person/Not for profit	Co-founder ILCC
		04/2020 – 04/2025	Lung Cancer Europe (LuCE)/Online and in person/Not for profit	President (2020–2025)

[5] **Legal representation** refers to the representation of natural or legal persons through other persons in accordance with national law. For example, the president of a company is the legal representative of that company.

Activities (2021 - 2025)	Yes/No	Period (From - To)	Information	Details
3. Regarding research related to lung cancer within the past 5 years: **A. Have you been an investigator in research studies on lung cancer?**	Yes ☒ No ☐	01/2021 – 12/2025	Developing novel inhaled bioengineered Extracellular Vesicle RNA based advanced therapeutics, delivered by tailored aerosol delivery technology for the treatment of lung cancer; Trinity College Dublin co-PI. Engaging people impacted by lung cancer in cancer research; PI Trini-Screen - Surveillance Screening of Staff and Students for SARS-CoV-2 in Trinity College Dublin; Co-PI	This study looked at EVs to treat lung cancer. I serve as a co-PI and help with, for example, experiments and supervision. No data has been published yet. This study looked at how we could engage more people impacted by lung cancer in research by creating resources and increasing awareness, I managed all aspects of the study. No data has been published yet. This study looked at saliva based assay to detect SARS-CoV-2. No data has been published yet. Note I have only included studies where I am PI/co-PI for the time period covered.

Activities (2021 - 2025)	Yes/No	Period (From - To)	Information	Details
B. If yes, for the aforementioned research studies, did you receive support[6]?	Yes ☒ No ☐	01/2021 – 12/2025	Grant; Horizon Europe (Private, Belgium); Consortium was awarded 12.8 million euro Grant; Irish Cancer Society (Charity, Ireland); 1,500 euro Support: Trinity College Dublin (University, Ireland); 50,000 euro	Developing novel inhaled bioengineered Extracellular Vesicle RNA based advanced therapeutics, delivered by tailored aerosol delivery technology for the treatment of lung cancer. Engaging people impacted by lung cancer in cancer research. Trini-Screen - Surveillance Screening of Staff and Students for SARS-CoV-2 in Trinity College Dublin

[6] **Support** refers to research support (i.e. grants, collaborations, sponsorships) as well as to non-monetary support (equipment, facilities) and other type of support (i.e. honoraria for being a speaker, holding a training).

4. Do you have membership in national or international organisations[7], including committees, working groups, collaborative platforms, managing bodies or scientific advisory bodies or any decision making bodies with an interest in lung cancer?	Yes ☒ No ☐	01/2021 – 12/2025	IASLC Women in Thoracic Oncology Taskforce; Denver, USA; Professional society	Member (2025-Present): Contribute to activities relating to the work of the organisation.
			ESMO Global Patient Advocacy Working Group; Lugano, Switzerland; Professional society	Member (2025–Present): Advocacy related activities, which are core to the work of the organisation.
			European Thoracic Oncology Platform (ETOP) Scientific Committee; Bern, Switzerland; Scientific research network	Member (2023–Present). Contribute to multidisciplinary discussions on thoracic oncology research priorities.
			IASLC DEI Taskforce; Denver, USA; Professional society	Member (2023-Present): Contribute to activities relating to the work of the organisation.
			Journal of Thoracic Oncology Clinical and Research Reports Editorial Board; Denver, USA; Peer reviewed journal	Editorial Board Member/Associate Editors (Approx. 2022–Present: Review and advise on manuscripts in thoracic oncology.
			Lung Health Check Steering Committee; Dublin, Ireland; Research consortium	Member (Approx. 2022–Present): Provided patient advocacy input to national lung cancer screening pilot
			European Cancer Organisation Patient Advisory Committee; Brussels, Belgium; Non-profit	Member (2018–2025): Contributed patient perspectives to European cancer policy discussions.
			IASLC Communications Committee; Denver, USA; Professional society	Member (2019-09/2025): Helped guide communication strategies and supported submissions for WCLC press programme.

Activities (2021 - 2025)	Yes/No	Period (From - To)	Information	Details
5. Do you have intellectual property rights (IPR)[8] related to lung cancer?	Yes ☐ No ☒	01/2021 – 12/2025	NA	NA
6. Within the past 5 years: **A. Have you provided any expert opinion or testimony in the field of lung cancer, for a legal entity or other body as part of a regulatory, legislative or judicial process?**	Yes ☐ No ☒	01/2021 – 12/2025	NA	NA

[7] **Organisation** refers to a governmental, international or non-profit organisation.

[8] **Intellectual property rights** refer to patents, trademarks, or copyrights (including pending applications) as well as proprietary know-how in a substance, technology or process.

Activities (2021 - 2025)	Yes/No	Period (From - To)	Information	Details
B. Have you held an office or other position, paid or unpaid, where you represented interests or defended an opinion in the field of lung cancer?	Yes ☒ No ☐	01/2021 – 12/2025	• Vice Chairperson, ILCC (Current) • Member, ESMO Global Patient Advocacy Working Group (Current) • Member, Lung Health Check Steering Committee (Current) • President, Lung Cancer Europe (LuCE) (Past) • Treasurer, Irish Lung Cancer Community (ILCC) (Past) • Member, ECO Patient Advisory Committee (Past) • Member of various IASLC committees and taskforces	Represented/represent patient perspectives and interests in lung cancer at Global, European and national level. Contributed/contribute to advocacy priorities, awareness, and policy development. Participated/participate in discussions and consensus-building. Contributed/contribute to organisation activities.
7. Do any of your immediate family members[9] have direct interests related to lung cancer that could undermine your independence?	Yes ☐ No ☒	01/2021 – 12/2025	NA	NA
8. Within the past 5 years, did you take part in other activities with interests related to lung cancer?	Yes ☐ No ☒	01/2021 – 12/2025	NA	NA

[9] **Immediate family members** refer to family members and relatives (spouse, parents, children, brothers and sisters, irrespective of whether they live at the same address or not) or other persons under the care of the members of the household of the expert.

Notes:

If you declared any direct interests of your immediate family members, it is your responsibility to inform them about how data on their interests are collected and published[10] before you send the DoI form to the Joint Research Centre (JRC), EC.

After submission of this form, you need to inform the JRC in case of any new activity during the course of the year by sending an e-mail as soon as possible at: JRC-CANCER-POLICY-SUPPORT@ec.europa.eu.

☒ **I hereby declare the information disclosed in this form is true and complete to the best of my knowledge.**
☒ **I agree my DoI form to be publicly available on the EC's web-hub on cancer screening and care, during the EC-LuC membership[11].**
☒ **I am informed that my personal data are stored, processed and published by the EC in accordance with Regulation (EU) 2018/1725[12].**

Name and Surname: **Anne-Marie Baird** **Date: 30/07/2026**

Signature: Anne-Marie Baird **Place: Dublin, Ireland**

[10] Personal data processing including the DoI
https://ec.europa.eu/dpo-register/detail/DPR-EC-00656
[11] Note: Technical measures are in place to ensure that search engines do not index the content from the DoI form.
[12] Protection of individuals with regard to the processing of personal data
https://eur-lex.europa.eu/legal-content/EN/TXT/?uri=CELEX%3A32018R1725